10/21/2026

Recent Oncology Related FDA Approvals and Expanded Indications

 

 

FDA approves expanded indication of Lilly's Jaypirca (pirtobrutinib) for non-covalent BTK inhibitor, for certain patients with previously untreated CLL/SLL

 

FDA approves GSKs Jemperli (dostarlimab) as immunotherapy for adults with MSI-HdMMR locally advanced rectal cancer

More Info